Eli Lilly’s Alzheimer’s therapy approved in Japan
Contributor since / Followers
jetcityimage/iStock Editorial via Getty Images
Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer’s disease has been approved for use in Japan.
Kisunla (donanemab-azbt), which is given via infusion once a month, is indicated for treatment of adults with early symptomatic Alzheimer’s disease.
The application was based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study, in which Kisunla demonstrated meaningful results by significantly slowing cognitive and functional decline in people with early symptomatic Alzheimer’s disease.
Japan is the second major market where Kisunla has received approval. The therapy, which was first approved in the U.S. in July 2024, competes against Biogen (BIIB) and Eisai’s (OTCPK:ESALF)(OTCPK:ESAIY) Leqembi (lecanemab).